Q-omics provides the consensus-scored LAD1 profile across patient tissues and cancer cell-line models. LAD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LAD1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LAD1 protein abundance shows 17,784 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, KIRC, and HNSC as cancer lineages where LAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAD1 survival associations across molecular data types. LAD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAD1 RNA expression–survival associations across cancer types. High LAD1 expression shows unfavorable associations in LUAD, BRCA, MESO and PAAD, but favorable associations in DLBC and LUSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LAD1 RNA expression.
This table summarizes LAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAD1 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in THCA, LUAD and LUSC. The KIRC box plot shows higher LAD1 RNA expression in normal versus tumor tissue (log2 FC = −3.599, t-test p < 0.001).
This table shows molecular features associated with LAD1 in patient tissues and cancer cell lines. In patient samples, LAD1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, LAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
